NR1H4 and metabolic dysfunction-associated steatohepatitis: To ascertain the engagement of brain FXR on energy homeostasis and BAT, additional experiments were performed using a different synthetic FXR agonist, tropifexor, which is currently undergoing phase 2 human clinical trials in NASH and PBC (Tully et al., 2017).